Ethosuximide

CHEMBL696 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

141.2 g/mol

LogP

0.4

Phase

4

This anticonvulsant medication works by blocking a specific type of calcium channel in brain cells that is responsible for the abnormal electrical activity causing absence seizures. It is the drug of choice for absence epilepsy.

Masse moléculaire

141,1700 g/mol

LogP

0,40

TPSA

46,20 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Epilepsy Migraine Breast Cancer Prostate Cancer Colorectal Cancer

Mécanisme d'action

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC1(C)CC(=O)NC1=O

InChI

InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

Molecular Formula

C7H11NO2

HBD / HBA

1 / 2

Liaisons Rotatives

1

Atomes Lourds

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This anticonvulsant medication works by blocking a specific type of calcium channel in brain cells that is responsible for the abnormal electrical activity causing absence seizures. It is the drug of choice for absence epilepsy.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Ethosuximide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL696. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3291. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Ethosuximide sur PillFYI

Structure

Données Clés

Formule: C7H11NO2
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.